Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck collaboration — Daiichi Sankyo (3 DXd ADC Oncology Programs) ($M) ($M)
Form 10-Q / 10-K Note 3/4 Collaborative Arrangements
Latest, Q2 2026
181
Period ended Jun 30, 2026
Change on a year earlier
-6.2%
193 in Q2 2025
History
14 quarters
Since Q1 2023
Sources
9
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Collaboration — Daiichi Sankyo (3 DXd ADC Oncology Programs) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 181 | -6.2% | Form 10-Q (filed 2026-08-07) ↗ |
| Q1 2026 | Mar 31, 2026 | 160 | +25.0% | Form 10-Q (filed 2026-05-04) ↗ |
| Q4 2025 | Dec 31, 2025 | -1 | – | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2025 | Sep 30, 2025 | 67 | – | Form 10-Q (filed 2025-11-05) ↗ |
| Q2 2025 | Jun 30, 2025 | 193 | +196.9% | Form 10-Q (filed 2026-08-07) ↗ |
| Q1 2025 | Mar 31, 2025 | 128 | +85.5% | Form 10-Q (filed 2026-05-04) ↗ |
| Q4 2024 | Dec 31, 2024 | 0 | -100.0% | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2024 | Sep 30, 2024 | 0 | – | Form 10-Q (filed 2025-11-05) ↗ |
| Q2 2024 | Jun 30, 2024 | 65 | – | Form 10-Q (filed 2025-08-05) ↗ |
| Q1 2024 | Mar 31, 2024 | 69 | – | Form 10-Q (filed 2025-05-02) ↗ |
| Q4 2023 | Dec 31, 2023 | 5,500 | – | Form 10-Q (filed 2024-11-06) ↗ |
| Q3 2023 | Sep 30, 2023 | 0 | – | Form 10-Q (filed 2024-11-06) ↗ |
| Q2 2023 | Jun 30, 2023 | 0 | – | Form 10-Q (filed 2024-08-05) ↗ |
| Q1 2023 | Mar 31, 2023 | 0 | – | Form 10-Q (filed 2024-05-03) ↗ |
Breakdown
What makes up collaboration — daiichi sankyo (3 dxd adc oncology programs) ($m)
- Daiichi Sankyo (3 DXd ADC Oncology Programs) — Current receivables from partner ($M)27 · Q2 2026
- Daiichi Sankyo (3 DXd ADC Oncology Programs) — Current payables / liabilities to partner ($M)100 · Q2 2026
- Daiichi Sankyo (3 DXd ADC Oncology Programs) — Cost of sales profit-sharing & manufacturing ($M)–
- Daiichi Sankyo (3 DXd ADC Oncology Programs) — Net R&D cost-sharing expense ($M)181 · Q2 2026
- Daiichi Sankyo (3 DXd ADC Oncology Programs) — Commercialization / SG&A expense sharing ($M)12 · Q2 2026
Cite this data
StockData. (2026). Merck Collaboration — Daiichi Sankyo (3 DXd ADC Oncology Programs) ($M) ($M), quarterly Q1 2023–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/collab_daiichisankyo
See every metric in the Merck KPI table. Data updated Oct 26, 2026.